2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-5 *(Cancelled)*

6. *(Currently amended)* A method for augmenting an immune responses in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient, wherein the flt3-ligand-derived dendritic cells augment the patient's tumor-specific immune responses.

7. *(Previously presented)* A method according to claim 6, further comprising the step of administering GM-CSF.

8-19 *(Cancelled)*

20. *(Currently amended)* A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells ~~enhance the patient's immune response to such disease~~ and administering a tumor antigen to the patient, wherein the flt3-ligand-derived dendritic cells augment the patient's tumor-specific immune responses.

21. *(Cancelled)*

22. *(Previously presented)* The method of claim 6, wherein the flt3-ligand is human flt3-ligand.

23. *(Previously presented)* The method of claim 22, wherein the flt3-ligand is soluble human flt3-ligand.

24. *(Previously presented)* The method of claim 23, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

25. *(Previously presented)* The method of claim 24, wherein the soluble human flt3-ligand comprises a polypeptide that is at least 90% identical to an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1 wherein Xaa

is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

26. *(Previously presented)* The method of claim 24, wherein the soluble human flt3-ligand comprises a polypeptide selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1, wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

27. *(Cancelled)*

28. *(Previously presented)* The method of claim 26, wherein the soluble human flt3-ligand comprises the amino acid sequence of residues 28-160 of SEQ ID NO:1.

29. *(Cancelled)*

30. *(Previously presented)* The method of claim 26, wherein the soluble human flt3-ligand comprises the amino acid sequence of residues 28-182 of SEQ ID NO:1.

31. *(Previously presented)* The method of claim 20, wherein the flt3-ligand is human flt3-ligand.

32. *(Previously presented)* The method of claim 31, wherein the flt3-ligand is soluble human flt3-ligand.

33. *(Previously presented)* The method of claim 32, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

34. *(Previously presented)* The method of claim 33, wherein the soluble human flt3-ligand comprises a polypeptide that is at least 90% identical to an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1, wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

35. *(Previously presented)* The method of claim 33, wherein the soluble human flt3-ligand comprises a polypeptide selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:1, wherein Xaa is an amino acid from 160 to 235, and wherein the polypeptide retains the capacity to bind flt3.

36. *(Cancelled)*

37. *(Previously presented)* The method of claim 35, wherein the soluble human flt3-ligand comprises the amino acid sequence of residues 28-160 of SEQ ID NO:1.

38. *(Cancelled)*

39. *(Previously presented)* The method of claim 35, wherein the soluble human flt3-ligand comprises the amino acid sequence of residues 28-182 of SEQ ID NO:1.

40. *(Previously presented)* The method of claim 6 wherein the cancerous disease is a tumor.

41. *(Previously presented)* The method of claim 20 wherein the cancerous disease is a tumor.

42. *(Previously presented)* The method of claim 40 wherein the tumor is a fibrosarcoma.

43. *(Previously presented)* The method of claim 41 wherein the tumor is a fibrosarcoma.

44. *(Previously presented)* The method of claim 6, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

45. *(Previously presented)* The method of claim 6, wherein the tumor antigen is in the form of an isolated tumor antigen.

46. *(Previously presented)* The method of claim 6, wherein the antigen is administered prior to administering flt3-ligand.

47. *(Previously presented)* The method of claim 6, wherein the antigen is administered concurrently with flt3-ligand.

48. *(Previously presented)* The method of claim 6, wherein the antigen is administered after administering flt3-ligand.

49. *(Previously presented)* The method of claim 20, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.

50. *(Previously presented)* The method of claim 20, wherein the tumor antigen is in the form of an isolated tumor antigen.

51. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered prior to administering flt3-ligand.

52. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered concurrently with administering flt3-ligand.

53. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered after administering flt3-ligand.

54. *(Withdrawn)* A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient, isolating dendritic cells from the patient, exposing the dendritic cells to a tumor antigen, and administering the dendritic cells to the patient.

55. *(Withdrawn)* The method of claim 54, wherein the tumor antigen is in the form of a tumor cell bearing said antigen.

56. *(Withdrawn)* The method of claim 54, wherein the tumor antigen is in the form of an isolated tumor antigen.